BRPI0513812A - método para produzir uma composição lìquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical - Google Patents

método para produzir uma composição lìquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical

Info

Publication number
BRPI0513812A
BRPI0513812A BRPI0513812-4A BRPI0513812A BRPI0513812A BR PI0513812 A BRPI0513812 A BR PI0513812A BR PI0513812 A BRPI0513812 A BR PI0513812A BR PI0513812 A BRPI0513812 A BR PI0513812A
Authority
BR
Brazil
Prior art keywords
radical
composition
hyperpolarized
producing
pyruvate
Prior art date
Application number
BRPI0513812-4A
Other languages
English (en)
Inventor
Mikkel Thaning
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0513812A publication Critical patent/BRPI0513812A/pt
Publication of BRPI0513812B1 publication Critical patent/BRPI0513812B1/pt
Publication of BRPI0513812B8 publication Critical patent/BRPI0513812B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Rectifiers (AREA)

Abstract

MéTODO PARA PRODUZIR UMA COMPOSIçãO LìQUIDA QUE COMPREENDE ¹³C-PIRUVATO HIPERPOLARIZADO, COMPOSIçãO, USO DA MESMA, RADICAL, E, USO DO RADICAL A invenção diz respeito a um método de produzir uma composição que compreende ¹³C-piruvato hiperpolarizado, à composição e seu uso como um agente formador de imagem para a formação de imagem RM.
BRPI0513812A 2004-07-30 2005-07-28 método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical BRPI0513812B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20043229 2004-07-30
PCT/NO2005/000281 WO2006011809A1 (en) 2004-07-30 2005-07-28 Method of producing a composition, composition and its use

Publications (3)

Publication Number Publication Date
BRPI0513812A true BRPI0513812A (pt) 2008-05-13
BRPI0513812B1 BRPI0513812B1 (pt) 2017-05-09
BRPI0513812B8 BRPI0513812B8 (pt) 2021-07-27

Family

ID=35058362

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513812A BRPI0513812B8 (pt) 2004-07-30 2005-07-28 método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical

Country Status (17)

Country Link
US (2) US20080095713A1 (pt)
EP (1) EP1797102B1 (pt)
JP (2) JP5367265B2 (pt)
KR (2) KR20070063504A (pt)
CN (1) CN101035796B (pt)
AU (1) AU2005267668B2 (pt)
BR (1) BRPI0513812B8 (pt)
CA (1) CA2575601C (pt)
DK (1) DK1797102T3 (pt)
ES (1) ES2545260T3 (pt)
IL (1) IL180897A (pt)
MX (1) MX2007001035A (pt)
NZ (1) NZ552898A (pt)
PL (1) PL1797102T3 (pt)
RU (1) RU2374252C2 (pt)
WO (1) WO2006011809A1 (pt)
ZA (1) ZA200701271B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014463D0 (en) * 2000-06-14 2000-08-09 Nycomed Amersham Plc NMR Method
KR20070063504A (ko) * 2004-07-30 2007-06-19 지이 헬스케어 에이에스 조성물의 제조 방법, 조성물 및 그의 용도
CA2628539C (en) * 2005-12-01 2014-04-29 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
PL1962912T3 (pl) * 2005-12-16 2013-03-29 Ge Healthcare As Sposób wytwarzania hiperpolaryzowanych karboksylanów amin organicznych
US20100233096A1 (en) * 2006-03-29 2010-09-16 Lerche Mathilde H Method to produce hyperpolarised carboxylates and sulphonates
JP5269791B2 (ja) 2006-08-30 2013-08-21 ジーイー・ヘルスケア・アクスイェ・セルスカプ 動的核分極（ｄｎｐ）方法並びに該方法で使用するための化合物及び組成物
EP2117607A4 (en) 2007-01-11 2012-08-08 Huntington Medical Res Inst PICTURES AND METHOD FOR THEIR USE
US8731640B2 (en) 2007-03-28 2014-05-20 General Electric Company Fluid path system for dissolution and transport of a hyperpolarized material
US20080240998A1 (en) * 2007-03-28 2008-10-02 Urbahn John A Fluid path system for dissolution and transport of a hyperpolarized material
US7470813B2 (en) 2007-03-30 2008-12-30 Ge Healthcare Limited Method for the production of pyruvic acid
CN101730504A (zh) * 2007-05-17 2010-06-09 通用电气公司 使用包含超极化13c-丙酮酸盐的成像介质使肿瘤分级的mr方法
US9227173B2 (en) 2007-06-22 2016-01-05 General Electric Company Methods for dynamic filtration of pharmaceutical products
US20100196283A1 (en) * 2007-07-26 2010-08-05 Lerche Matilde H Method and imaging medium for use in the method
EP2902041A1 (en) 2007-12-19 2015-08-05 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
CN101951963B (zh) * 2007-12-21 2013-07-17 通用电气健康护理有限公司 Mr成像剂、成像介质和其中使用该成像介质的成像方法
WO2009129265A1 (en) 2008-04-14 2009-10-22 Huntington Medical Research Institutes Methods and apparatus for pasadena hyperpolarization
US8763410B2 (en) 2008-04-21 2014-07-01 General Electric Company Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media
WO2009133169A1 (en) 2008-05-02 2009-11-05 General Electric Company Method of determining alanine transaminase (alt) activity by 13c-mr detection using hyperpolarised 13c-pyruvate
BRPI1013677A2 (pt) 2009-04-02 2016-04-26 Ge Healthcare Ltd método para detectar inflamação ou infecção, e, usos de um 13c-piruvato hiperpolarizado, e de um meio de formação de imagem.
EP2476009A1 (en) 2009-09-10 2012-07-18 GE Healthcare UK Limited 13c-mr detection using hyperpolarised 13c-fructose
DE102009054956A1 (de) * 2009-12-18 2011-06-22 Siemens Aktiengesellschaft, 80333 Magnetresonanztomographie-Bildgebung
EP2555803B1 (en) 2010-04-08 2018-09-12 Bracco Imaging S.p.A Process for preparing hyperpolarized substrates and method for mri
JP5879333B2 (ja) 2010-05-03 2016-03-08 ジーイー・ヘルスケア・リミテッド Ｌｄｈ活性を決定するための過分極乳酸塩造影剤
US20130149250A1 (en) * 2011-06-23 2013-06-13 The Regents Of The University Of California Hyperpolarized agents for mri characterization of redox systems in vivo
EP2766050B1 (en) 2011-10-12 2018-09-05 Bracco Imaging S.p.A Process for the preparation of hyperpolarized derivatives for use in mri analysis
EP2788035B1 (en) 2011-12-05 2016-03-09 Bracco Imaging S.p.A Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis
WO2014118258A1 (en) 2013-01-31 2014-08-07 Bracco Imaging Spa Hyperpolarized esters as metabolic markers in mr
EP3016687B1 (en) 2013-07-01 2017-08-09 Bracco Imaging S.p.A Hyperpolarized 1-13c-1,1-bis(acetoxy(methyl))-2,2'-cyclopropane as metabolic marker for mr
US9874622B2 (en) 2013-09-27 2018-01-23 General Electric Company Hyperpolarized media transport vessel
CN120574245B (zh) * 2025-08-04 2025-12-02 中国科学院精密测量科学与技术创新研究院 一种含氟三苯甲基自由基化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010419A1 (en) 1987-06-23 1988-12-29 Cockbain, Julian, Roderick, Michaelson Improvements in and relating to magnetic resonance imaging
GB8817137D0 (en) 1988-07-19 1988-08-24 Nycomed As Compositions
CA2075818A1 (en) 1990-02-12 1991-08-13 Mikkel Joergensen Triarylmethyl radicals and the use of inert carbon free radicals in mri
DK0662004T3 (da) 1991-08-09 1998-10-19 Nycomed Innovation Ab Anvendelse af stabile frie radikaler ved magnetiskresonans-billeddannnelse
US5728370A (en) 1993-04-02 1998-03-17 Nycomed Imaging As Free Radicals
PL325428A1 (en) 1995-09-08 1998-07-20 Nycomed Imaging As Method of determining the oxygen concentration in a sample
EP0966414B1 (en) 1997-03-06 2003-06-04 Amersham Health AS Triarylmethyl free radicals as image enhancing agents
CN1269015A (zh) 1997-06-19 2000-10-04 耐克麦德英梅金公司 使用体外极化磁共振成像剂的奥氏磁共振成像方法
US6278893B1 (en) * 1998-01-05 2001-08-21 Nycomed Imaging As Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent
US6232497B1 (en) 1998-12-23 2001-05-15 Skw Trostberg Aktiengesellschaft Method for producing alkali metal and alkaline earth metal pyruvates
GB0014463D0 (en) 2000-06-14 2000-08-09 Nycomed Amersham Plc NMR Method
JP4061192B2 (ja) 2000-11-03 2008-03-12 ジーイー・ヘルスケア・アクスイェ・セルスカプ 分極ｎｍｒ試料用のデバイス及び方法
US6617169B2 (en) * 2001-03-30 2003-09-09 Mclean Hospital Corporation Two-dimensional MR spectroscopy techniques
US6486671B1 (en) * 2001-05-14 2002-11-26 Ge Medical Systems Global Technologies Company Llc MRI image quality improvement using matrix regularization
US6958244B2 (en) * 2002-04-12 2005-10-25 Bruker Biospin Corp. Low-conductivity buffers for magnetic resonance measurements
KR20070063504A (ko) * 2004-07-30 2007-06-19 지이 헬스케어 에이에스 조성물의 제조 방법, 조성물 및 그의 용도
CA2575473C (en) * 2004-07-30 2013-02-19 Ge Healthcare As Radicals and their use as paramagnetic agents in a dnp process

Also Published As

Publication number Publication date
HK1107691A1 (en) 2008-04-11
ZA200701271B (en) 2008-05-28
KR20130028989A (ko) 2013-03-20
US20080213186A1 (en) 2008-09-04
US9023320B2 (en) 2015-05-05
KR20070063504A (ko) 2007-06-19
IL180897A0 (en) 2007-07-04
JP2008508266A (ja) 2008-03-21
JP5367265B2 (ja) 2013-12-11
NZ552898A (en) 2011-02-25
IL180897A (en) 2010-11-30
DK1797102T3 (en) 2015-08-24
AU2005267668B2 (en) 2011-10-20
JP5745470B2 (ja) 2015-07-08
EP1797102A1 (en) 2007-06-20
EP1797102B1 (en) 2015-05-27
PL1797102T3 (pl) 2015-10-30
BRPI0513812B8 (pt) 2021-07-27
JP2012236832A (ja) 2012-12-06
ES2545260T3 (es) 2015-09-09
CN101035796A (zh) 2007-09-12
CN101035796B (zh) 2011-06-22
CA2575601A1 (en) 2006-02-02
MX2007001035A (es) 2007-07-11
WO2006011809A1 (en) 2006-02-02
CA2575601C (en) 2013-05-28
KR101475635B1 (ko) 2014-12-22
AU2005267668A1 (en) 2006-02-02
RU2007102843A (ru) 2008-09-10
RU2374252C2 (ru) 2009-11-27
BRPI0513812B1 (pt) 2017-05-09
US20080095713A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
CL2023002204A1 (es) Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
BR112018006298A2 (pt) "adjunto compressível com fibras espaçadoras cruzadas"
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CL2013000100A1 (es) Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.
CU20090058A7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
BRPI0410503B8 (pt) composição tópica e uso da composição
BR122019021238B8 (pt) uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY28348A1 (es) Compuestos novedosos
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
CY1118835T1 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
BRPI0510487A (pt) agentes de contraste para estudo por imagens de perfusão do miocárdio
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07D 519/00 (2006.01), A61B 5/055 (2006.01), A61K

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.